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Background/Purpose: The ORBIT I trial, a ﬁrst-in-man study, was conducted to evaluate the safety and perfor-
mance of the orbital atherectomy system (OAS) in treating de novo calciﬁed coronary lesions.
Methods/Materials: Fifty patients were enrolled between May and July 2008 based on several criteria, and were
treatedwith theOAS followed by stent placement. The safety and performance of theOASwere evaluated bypro-
cedural success, device success, and overall major adverse cardiovascular event (MACE) rates, including cardiac
death, myocardial infarction (MI) and need for target lesion revascularization (TLR). Our institution enrolled and
treated 33 of the 50 patients and continued follow-up for 5 years.
Results: Average age was 54 years and 91% were males. Mean lesion length was 15.9 mm. Device success was
100%, and average number of orbital atherectomy devices (OAD) used per patient was 1.3. Stents were placed
directly after OAS in 31/32 patients (96.9%). All stents (average stent per lesion 1.1) were successfully deployed
with 0.3% residual stenosis. The overall cumulative MACE rate was 6.1% in-hospital, 9.1% at 30 days, 12.1% at
6 months, 15.2% at 2 years, 18.2% at 3 years and 21.2% at 5 years (4 total cardiac deaths). None of the patients
had Q-wave MIs. Angiographic complications were observed in 5 patients. No ﬂow/slow ﬂow due to distal em-
bolization was observed.
Conclusions: The ORBIT I trial suggests that OAS treatment continues to offer a safe and effective method to change
compliance of calciﬁed coronary lesions to facilitate optimal stent placement in these difﬁcult-to-treat patients.
© 2015 Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Calciﬁed coronary lesions are common,with 38% of all lesions show-
ing calciﬁcation as detected by angiography and 73% of all lesions show-
ing calciﬁcation as detected by intravascular ultrasound (IVUS) [1].
Calciﬁc deposits are found more frequently and in greater amounts in
elderly individuals and more advanced lesions [2].
Efforts to control coronary artery calciﬁcation (CAC) with medical
therapy have not been successful. Despite advances in interventional
equipment and techniques, the treatment of calciﬁed coronary lesions
continues to pose an ongoing challenge [3]. Calciﬁed lesions respondartery calciﬁcation; CAD, coro-
ravascular ultrasound; MACE,
ction; OA, orbital atherectomy;
system; PCI, percutaneous cor-
limus-eluting stent; TLR, target
Sciences (CIMS), Ahmedabad
79 2771 2770.
icle under the CC BY-NC-ND license (poorly to balloon angioplasty, increase the likelihood of procedural fail-
ure, and are associatedwith a high frequency of restenosis and target le-
sion revascularization (TLR) [4]. Coronary calciﬁcationmay impair stent
delivery and expansion, and damage the polymer/drug coating,
resulting in impaired drug delivery and predisposition to restenosis
and stent thrombosis [5]. Attempts to remedy incomplete stent expan-
sion with aggressive high pressure balloon dilatation may result in cor-
onary artery rupture [6].
As a remedy to this problem, lesion preparation may be recom-
mended to facilitate coronary stent implantation in these difﬁcult le-
sions. Another goal of lesion preparation is to reduce plaque shift and
allow optimal stent expansion [7]. Rotational atherectomy (RA) is one
of the procedures used to modify calciﬁed plaques and improve overall
success of stent implantation, but distal embolization of debris from the
procedure is a concern. The incidence of slow or no ﬂow in these proce-
dures has been reported to be 6% to 15% [8,9].
The Diamondback 360® Coronary Orbital Atherectomy System
(OAS) (Cardiovascular Systems, Inc., St. Paul, MN), which has been
used successfully to treat peripheral vascular stenosis, has also been
evaluated for the treatment of calciﬁed coronary lesions. The ORBIT Ihttp://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Lesion characteristics.
Procedural Information Observations n/N (%) (n = 33)
Target Vessel
Left anterior descending 20/33 (60.6%)
Left circumﬂex artery 7/33 (21.2%)
Right coronary artery 6/33 (18.2%)
American College of Cardiology/American Heart Association (ACC/AHA) lesion class:
Type A 2/33 (6.1%)
Type B1 11/33 (33.3%)
Type B2 20/33 (60.6%)
Balloon angioplasty predilation prior to IVUS 6/33 (18.2%)
Mean lesion length (mm), mean ± SD 15.9 ± 4.5
Reference vessel diameter (mm), mean ± SD 3.2 ± 0.4
Mean lumen diameter (mm), mean ± SD 1.3 ± 1.2
Table 1
Baseline characteristics of enrolled patients.
Baseline Characteristic Observations n/N (%)
Average age (years; mean ± SD) 54.4 ± 9.1
Gender (males) 30/33 (90.9%)






Stable angina 29/32 (90.6%)
Canadian Cardiovascular Society Angina class I 12/32 (37.5%)
Canadian Cardiovascular Society Angina class II 17/32 (53.1%)
Canadian Cardiovascular Society Angina class III 3/32 (9.4%)
Percutaneous coronary intervention history (N30
days prior to study)
5/33 (15.2%)
Coronary bypass graft surgery (prior to study) 1/33 (3.0%)
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after OAS treatment of de novo calciﬁed coronary lesions in adults. Ini-
tial, 6-month [10] and 3-year results [11] have been previously pub-
lished. Here, we report on the 5-year follow-up of a subset of 33
patients enrolled at one of the participating centers.Table 3
OAS treatment parameters and change in vessel diameter.
Procedural Information Observations
Average number of OAD used per subject (n = 32), mean ± SD 1.3 ± 0.4
Average number of stents used per lesion (n = 32), mean ± SD 1.1 ± 0.3
Average stent diameter (mm) (n = 35), mean (range) 3.1 (2.5–4.0)
Average stent length (mm) (n = 35), mean (range) 22 (9–33)
Type of stent, n/N (%)
Cypher (SES) 13/35 (37.1)
Endeavor (ZES) 22/35 (62.9)
% Diameter stenosis, mean ± SD
Pre OAS (n = 33) 85.6 ± 7.8
Post OAS (n = 32) 39.4 ± 10.1
Post stent (n = 32) 0.3 ± 1.8
Change (lesion modiﬁcation) (n = 32) 45.9 ± 11.8⁎
OAD: orbital atherectomydevice; OAS: orbital atherectomy system; SES: sirolimus-eluting
stent; ZES: zotarolimus-eluting stent.
⁎ p b 0.0001.2. Material and methods
The ORBIT I trial was a prospective, non-randomized, multi-center,
feasibility study that evaluated the safety, performance and effective-
ness of the OAS. A total of 50 patients were enrolled at 2 sites in India
(NewDelhi, n= 17; Ahmedabad, n=33). One of the participating cen-
ters enrolled and followed 33 of these ORBIT I patients up to 5 years.
Ethics committee approval was received and patients who gave written
informed consent and met all inclusion and no exclusion criteria were
enrolled. Inclusion and exclusion criteria have been previously de-
scribed [10]. Brieﬂy, patients with de novo coronary lesions with stenosis
≥50% and b100%, and at least 1 quadrant of calciﬁcation via IVUS were
enrolled, and patients with prior percutaneous coronary intervention
(PCI) or surgery or very recentmyocardial infarction (MI)were excluded.
All procedures were performed electively and performed in the
standard fashion. The procedure has been previously described [10]. De-
vice success was deﬁned as ﬁnal achievement of≤50% residual stenosis
of the target lesion after OAS use only (before stent placement or any
other adjunctive treatment), without a device malfunction. Procedural
success was deﬁned as ≤20% residual stenosis after stent placement.
Change (lesion modiﬁcation) was based on pre- and post-diameter ste-
nosis of lesions treated with OAS. Patients were followed at 30 days,
3 months, 6 months, 2 years, 3 years and 5 years post-index treatment.
The safety of the OAS was evaluated by procedural success, device suc-
cess, and overall major adverse cardiovascular event (MACE) rates, in-
cluding cardiac death, MI and need for TLR. Reporting of angiographic
complications consisted of no ﬂow or slow ﬂow due to distal emboliza-
tion, abrupt or threatened closure of the treated vessel, spasm requiring
any surgical intervention (which could not be resolved via medica-
tions), dissection, perforation and other events seen angiographically.
Data collected on study speciﬁc case report forms were analyzed.
Continuous variables including age, lesion characteristics, and OAS
treatment parameters are presented as mean ± SD. The categorical
data, including angina class, number of vessels, stents, and cumulative
MACE rates are presented by frequency and percentage of patients. Ad-
verse events were judged by the investigators as to their relatedness to
the study device and treatment procedure to be “not related”, “undeter-
mined”, or “related”. Kaplan Meier survival probability estimates were
determined. P-values were determined using GraphPad Prism Version
5.4; p b 0.05 was considered as statistically signiﬁcant.3. Results
A total of 33 patients, enrolled at a single center between May and
July 2008, were followed for 5 years. Patient demographics have been
previously reported [10] and are provided in Table 1. Lesions were clas-
siﬁed according to the ACC/AHA system as Type A (6%), Type B1 (33%),
and Type B2 (61%). Mean lesion lengthwas 15.9mm. Table 2 shows the
lesion characteristics in details.
Procedural success (≤20% residual stenosis after stent placement)
was achieved in 97% (32/33) of patients. In one subject, the IVUS cathe-
ter could not cross the lesion due to severe calciﬁcation and OAS treat-
ment was not performed. Device success was 100% (32/32) (b50%
residual stenosis after OAS use only with no device malfunction). Aver-
age number of orbital atherectomy devices (OAD) used per patient was
1.3. Stents were placed directly after OAS in 31/32 patients (96.9%). All
stents (average stent per lesion 1.1) were successfully deployed with
0.3% residual stenosis. In only 1/32 patients (3.1%) was balloon angio-
plasty performed after OAS treatment and prior to stent placement. All
post-atherectomy stents implanted were drug-eluting stents (DES)
(sirolimus-eluting stent, 37.1%; zotarolimus-eluting stent, 62.9%). The
pre- to post-atherectomy and post-stent placement difference in mean
diameter stenosis was statistically signiﬁcant (p b 0.0001). Table 3 pre-
sents the OAS treatment parameters and change in vessel diameter.
The observedMACE rates are as shown in Table 4. The overall cumu-
lative MACE rate was 6.1% in-hospital (2 non-Q wave MIs), 9.1% at
30 days (1 additional non-Q-wave MI leading to TLR), 12.1% at
6 months (1 event of cardiac death), 15.2% at 2 years (1 additional
event of cardiac death, 18.2% at 3 years (1 additional event of cardiac
death) and 21.2% at 5 years (1 additional event of cardiac death [4
total cardiac deaths]). None of the patients had Q-wave MIs. Kaplan
Meier survival probability estimates are placed in Table 4.
Angiographic complications were observed in 5 patients (2 minor
dissections, 1 major dissection and 2 perforations). There was no occur-
rence of no ﬂow/slow ﬂow due to distal embolization.
Table 4
Cumulative MACE rates for 5 years.
In-Hospital 30 day Follow-Up 6 month Follow-Up 2 year Follow-Up 3 year Follow-Up 5 year Follow-Up
Cardiac Death 0 0 3% (1/33) 6.1% (2/33) 9.1% (3/33) 12.1% (4/33)
Q-wave MI 0 0 0 0 0 0
Non Q-wave MI 6.1% (2/33) 6.1% (2/33) 6.1% (2/33) 6.1% (2/33) 6.1% (2/33) 6.1% (2/33)
TLR 0 3% (1/33) 3% (1/33) 3% (1/33) 3% (1/33) 3% (1/33)
MACE Rate 6.1% (2/33) 9.1% (3/33) 12.1% (4/33) 15.2% (5/33) 18.2% (6/33) 21.2% (7/33)
KM estimate NA 1 0.99 0.98 0.97 0.96
MI: Myocardial Infarction; TLR: Target Lesion Revascularization; MACE: Major Adverse Cardiovascular Event; KM estimate: Kaplan Meier survival probability estimate.
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Severe coronary calciﬁcation should be considered as amarker of ad-
vanced atherosclerosis and an independent predictor of worse progno-
sis [12]. PCI of calciﬁed lesions was independently predictive of adverse
ischemic outcomes, including deﬁnite stent thrombosis and unplanned
ischemia driven repeat revascularizationwithin 1 year post-PCI, as com-
pared with patients in whom all target lesions had no or only mild cal-
ciﬁcation [13].
CAC increases the likelihood of procedural failure and complications
like dissection and acute vessel closure, MI, restenosis, and MACE after
balloon angioplasty [14–16]. Although implantation of bare-metal
stents (BMS) compared with balloon angioplasty improves acute and
long term event-free survival in both calciﬁed and noncalciﬁed lesions,
stent underexpansion, asymmetric expansion, and malapposition are
frequently observed in heavily calciﬁed lesions [3]. Several studies
have shown that DES are more effective than BMS in calciﬁed lesions
[17–19]. However, data with regard to the absolute efﬁcacy of DES in
calciﬁed lesions are conﬂicting [20,21].
Cutting and scoring balloons do not remove calcium. They improve
vessel compliance by creating discrete incisions in the atherosclerotic
plaque, enabling greater lesion expansion and reducing recoil while
preventinguncontrolled dissections [22]. However,MI and vessel perfo-
ration were more common with cutting balloon atherotomy [23]. In
contrast, high-speed RA ablates coronary calcium. BMS implantation
after RA in calciﬁed lesions facilitates greater acute lumen gains, al-
though restenosis rates remained high [18,24]. DES use after RA has
been associatedwith better long-term outcomes [25] although observa-
tional studies reported inconsistent results [26]. In the prospective, ran-
domized ROTAXUS trial routine lesion preparation using RA did not
reduce late lumen loss of DES at 9months in complex calciﬁed coronary
lesions [27]. Rates of restenosis, TLR, deﬁnite stent thrombosis, and
MACE were not signiﬁcantly different between the groups. Thus, RA
cannot routinely be recommended in calciﬁed lesions if full balloon ex-
pansion is anticipated before DES. The latest PCI guidelines state that RA
is a reasonable strategy in calciﬁed lesions that are not crossable by a
balloon catheter or adequately dilated before stent implantation (Class
IIa, Level of Evidence: C) [6].
Orbital atherectomy (OA) produces a differential sanding effect on
plaque surfaces, producing 2 μm particles in average [28]. This recently
U.S. Food and Drug Administration-approved system consists of a
diamond-coated crown, which rotates over the atherectomy guidewire
as it orbits around the vessel, exerting a centrifugal force on the vessel
wall. The device allows control of ablation depth, with increasing rota-
tional speed (ranging from 60,000 to 120,000 rpm) translating to a larg-
er orbit of rotation, besides allowing greater blood ﬂow with less heat
generation and thermal injury during the procedure. In contrast to RA,
it is an abrasive burr that rotates concentrically on the guidewire.
Treatment of challenging calciﬁed lesions often leads to increased
MACE rates as the lesions are more complex and difﬁcult to treat. In
the ROTAXUS study, the MACE rate for calciﬁed lesions treated with
RA and DES was approximately 24% at 9 months [27]. In contrast, this
subset of the ORBIT I trial demonstrated that patients with calciﬁed cor-
onary artery lesions treated with OAS and stent placement had lower
MACE rates with up to 5 years of follow-up (9.1% at 30 days, 12.1% at6 months, 15.2% at 2 years, 18.2% at 3 years and 21.2% at 5 years). The
MACE rates for this study subset are also less than the MACE rates re-
ported in the few DES trials that have included moderate and severely
calciﬁed lesion [29,30]. The ORBIT II prospective, multi-center clinical
trial of 443 patients using OA was completed in the United States. In
the ORBIT II the MACE rate was 10.4% at 30 days, [31] and 16.4% at
1 year [32]. Future long-term outcome studies need to be planned to
evaluate the optimal technique for OA use and to determine whether
routine use of OA before current-generation DES improves outcomes
in high-risk patients with CAC.
5. Conclusions
In patients undergoing PCI of heavily calciﬁed lesions, optimized
methods of lesion preparation and calcium ablation are needed. The
ORBIT I trial, a clinical pilot study, suggests that the OAS treatment may
offer effective method to modify calciﬁed coronary lesion compliance
to facilitate optimal stent placement in these difﬁcult-to-treat patients
with acceptable levels of safety up to 5 years post-index procedure.
6. Study limitations
This trial has several limitations, which have been previously de-
scribed [10,11]. The ORBIT I trial was designed as a feasibility study
and, therefore, lacked a control group for comparison. Other key limita-
tions are that this subset included a small number of patients treated
with OAS at a single center and the lack of core lab adjudication in this
pilot study. As with any new technology, a learning curve is present.
Long-term follow-up has been conducted on subjects of a single
site only. Additional experience may reduce the incidence of intra-
procedural complications.
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